CT37-mAb

CT37-mAb is a preclinical-stage monoclonal antibody developed by Stromatis Pharma that targets Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5). CEACAM5 is a cell-surface glycoprotein overexpressed in a variety of epithelial malignancies, including colorectal, pancreatic, and non-small cell lung cancers, making it a significant target for cancer immunotherapy. While the specific downstream mechanism (such as antibody-dependent cellular cytotoxicity or direct signaling inhibition) has not been fully characterized in public records, the antibody is designed to selectively bind CEACAM5-expressing tumor cells. CT37-mAb is part of a broader portfolio at Stromatis Pharma focused on CEACAM-related pathways, which also includes antibody-drug conjugates and CAR-T cell therapies.